Elotuzumab for the treatment of multiple myeloma

Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yucai, Sanchez, Larysa, Siegel, David S., Wang, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946088/
https://www.ncbi.nlm.nih.gov/pubmed/27417553
http://dx.doi.org/10.1186/s13045-016-0284-z
_version_ 1782442965340258304
author Wang, Yucai
Sanchez, Larysa
Siegel, David S.
Wang, Michael L.
author_facet Wang, Yucai
Sanchez, Larysa
Siegel, David S.
Wang, Michael L.
author_sort Wang, Yucai
collection PubMed
description Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.
format Online
Article
Text
id pubmed-4946088
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49460882016-07-16 Elotuzumab for the treatment of multiple myeloma Wang, Yucai Sanchez, Larysa Siegel, David S. Wang, Michael L. J Hematol Oncol Review Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM. BioMed Central 2016-07-15 /pmc/articles/PMC4946088/ /pubmed/27417553 http://dx.doi.org/10.1186/s13045-016-0284-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wang, Yucai
Sanchez, Larysa
Siegel, David S.
Wang, Michael L.
Elotuzumab for the treatment of multiple myeloma
title Elotuzumab for the treatment of multiple myeloma
title_full Elotuzumab for the treatment of multiple myeloma
title_fullStr Elotuzumab for the treatment of multiple myeloma
title_full_unstemmed Elotuzumab for the treatment of multiple myeloma
title_short Elotuzumab for the treatment of multiple myeloma
title_sort elotuzumab for the treatment of multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946088/
https://www.ncbi.nlm.nih.gov/pubmed/27417553
http://dx.doi.org/10.1186/s13045-016-0284-z
work_keys_str_mv AT wangyucai elotuzumabforthetreatmentofmultiplemyeloma
AT sanchezlarysa elotuzumabforthetreatmentofmultiplemyeloma
AT siegeldavids elotuzumabforthetreatmentofmultiplemyeloma
AT wangmichaell elotuzumabforthetreatmentofmultiplemyeloma

Ejemplares similares